Athenex Expands its Strategic Partnership with Guangzhou Xiangxue Pharmaceutical through a Licensing Agreement for its Product Candidates Oral Paclitaxel and Oral Irinotecan, as well as Tirbanibulin Ointment, in China, Hong Kong and MacaoAthenex, Inc. • December 16th, 2019 • Pharmaceutical preparations
The agreement covers China, Hong Kong and Macao (the “Territory”) and represents an expansion of the existing relationship between the two companies.
LICENSE AGREEMENT by and between ATHENEX, INC. and GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD. December 12, 2019License Agreement • December 16th, 2019 • Athenex, Inc. • Pharmaceutical preparations
THIS LICENSE AGREEMENT (this “Agreement”) is made as of December 12, 2019 (the “Effective Date”), by and between ATHENEX, INC., a corporation organized and existing under the laws of the State of Delaware USA and having its principal office at Conventus Building, 1001 Main Street, Suite 600, Buffalo, New York 14203, USA (“Athenex”) and GUANGZHOU XIANGXUE PHARMACEUTICAL CO., LTD., a Chinese company existing under the laws of China and having its principal office at 2 Jinfengyuan Road, Guangzhou, China (“XPH”) or its affiliates.
